{"PubmedArticle": [{"MedlineCitation": {"OtherID": [], "SpaceFlightMission": [], "KeywordList": [], "CitationSubset": ["IM"], "InvestigatorList": [], "OtherAbstract": [{"AbstractText": ["La Soci\u00e9t\u00e9 de pneumologie de langue fran\u00e7aise d\u00e9finie <b>l\u2019exacerbation aigu\u00eb de bronchopneumopathie chronique obstructive</b> comme une majoration des sympt\u00f4mes respiratoires au-del\u00e0 des variations quotidiennes (en pratique, d\u2019une dur\u00e9e\u00a0\u2265\u00a048\u00a0h ou justifiant une modification th\u00e9rapeutique). <b>La cause de ces exacerbations est principalement infectieuse</b>\u00a0: virale (rhinovirus, virus influenzae et parainfluenzae, coronavirus, ad\u00e9novirus et virus respiratoire syncytial) ou bact\u00e9rienne (principalement, <i>Haemophilus influenzae, Streptococcus pneumoniae</i> et <i>Moraxella catarrhalis</i>). Elles peuvent \u00e9galement r\u00e9sulter de l\u2019exposition \u00e0 certains polluants\u00a0: NO<sub>2</sub>, SO<sub>2</sub>, ozone et pollution particulaire (PM10 et PM2,5). Elle reste ind\u00e9termin\u00e9e dans pr\u00e8s de 30\u00a0% des cas. <b>Les diagnostics diff\u00e9rentiels</b> incluent les pneumopathies infectieuses, les pneumothorax, les pouss\u00e9es d\u2019insuffisance cardiaque et les embolies pulmonaires. <b>La pr\u00e9sence de signes de gravit\u00e9 conditionne l\u2019hospitalisation</b>\u00a0: signes d\u2019insuffisance respiratoire aigu\u00eb, de choc ou de d\u00e9faillance neurologique, mais aussi en cas de patient fragile, d\u2019absence de soutien familial \u00e0 domicile ou de r\u00e9ponse au traitement initial. <b>Le traitement</b> consiste en une majoration des bronchodilatateurs, une kin\u00e9sith\u00e9rapie respiratoire, une antibioth\u00e9rapie en cas d\u2019expectoration franchement purulente. La prescription de cortico\u00efdes syst\u00e9miques ne doit pas \u00eatre syst\u00e9matique. La dose recommand\u00e9e est de 0,5\u00a0mg/kg sur une courte p\u00e9riode (5\u20137 jours). Lors d\u2019une hospitalisation, une oxyg\u00e9noth\u00e9rapie et une thromboprophylaxie peuvent \u00eatre instaur\u00e9es. La ventilation non invasive est principalement indiqu\u00e9e en cas de persistance d\u2019une hypercapnie malgr\u00e9 un traitement m\u00e9dical optimal. Que le patient soit pris en charge en ambulatoire ou en hospitalisation, une r\u00e9\u00e9valuation clinique \u00e0 48\u201372\u00a0h est indispensable.\u2028\u2028"], "CopyrightInformation": "Copyright \u00a9 2014 Elsevier Masson SAS. All rights reserved."}], "GeneralNote": [], "PMID": "25451635", "DateCompleted": {"Year": "2015", "Month": "02", "Day": "11"}, "DateRevised": {"Year": "2024", "Month": "07", "Day": "28"}, "Article": {"Language": ["fre"], "ArticleDate": [{"Year": "2014", "Month": "10", "Day": "23"}], "ELocationID": ["10.1016/j.lpm.2014.03.034", "S0755-4982(14)00463-1"], "Journal": {"ISSN": "2213-0276", "JournalIssue": {"Volume": "43", "Issue": "12 Pt 1", "PubDate": {"Year": "2014", "Month": "Dec"}}, "Title": "Presse medicale (Paris, France : 1983)", "ISOAbbreviation": "Presse Med"}, "ArticleTitle": "[Management of COPD exacerbations: from primary care to hospitalization].", "Pagination": {"StartPage": "1359", "EndPage": "1367", "MedlinePgn": "1359-67"}, "Abstract": {"AbstractText": ["The Soci\u00e9t\u00e9 de pneumologie de langue fran\u00e7aise defines acute exacerbation of chronic obstructive pulmonary disease (AE COPD) as an increase in daily respiratory symptoms, basically duration \u2265 48h or need for treatment adjustment. Etiology of EA COPD are mainly infectious, viral (rhinovirus, influenzae or parainfluenzae virus, coronavirus, adenovirus and respiratory syncytial virus) or bacterial (Haemophilus influenzae, Streptococcus pneumoniae, or Moraxella catarrhalis). Pollutant exposure can also lead to AE COPD, such as NO2, SO2, ozone or particulates (PM10 and PM2.5). In 30% the etiology remains unknown. Differential diagnoses of AE COPD include infectious pneumonia, pneumothorax, acute heart failure and pulmonary embolism. Presences of signs of severity impose hospitalization: signs of respiratory distress, shock, acute confusion but also fragile patients, insufficient home support or absence of response to initial treatment. AE COPD treatments consist on increase in bronchodilators, chest physiotherapy, and antibiotics if sputum is frankly purulent. Systemic corticosteroids should not be systematic. Recommended dose is 0.5 mg/kg on short course (5-7 days). During hospitalization, oxygen supplementation and thromboprophylaxis could be prescribed. The main interest in non-invasive ventilation is persistent hypercapnia despite optimal medical management. During ambulatory management or hospitalization, clinical assessment at 48-72 h is mandatory."], "CopyrightInformation": "Copyright \u00a9 2014 Elsevier Masson SAS. All rights reserved."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "H\u00f4pital Pontchaillou, universit\u00e9 de Rennes 1, service de pneumologie, 35033 Rennes, France; IRSET UMR 1085, universit\u00e9 de Rennes 1, 35065 Rennes, France. Electronic address: Stephane.JOUNEAU@chu-rennes.fr."}], "LastName": "Jouneau", "ForeName": "St\u00e9phane", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "H\u00f4pital Pontchaillou, universit\u00e9 de Rennes 1, service de pneumologie, 35033 Rennes, France."}], "LastName": "Brinchault", "ForeName": "Graziella", "Initials": "G"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "H\u00f4pital Pontchaillou, universit\u00e9 de Rennes 1, service de pneumologie, 35033 Rennes, France."}], "LastName": "Desrues", "ForeName": "Beno\u00eet", "Initials": "B"}], "PublicationTypeList": ["English Abstract", "Journal Article", "Review"], "VernacularTitle": "Prise en charge des exacerbations: de la ville \u00e0 l'h\u00f4pital."}, "MedlineJournalInfo": {"Country": "France", "MedlineTA": "Presse Med", "NlmUniqueID": "8302490", "ISSNLinking": "0755-4982"}, "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Combined Modality Therapy"}, {"QualifierName": [], "DescriptorName": "Diagnosis, Differential"}, {"QualifierName": [], "DescriptorName": "Disease Progression"}, {"QualifierName": [], "DescriptorName": "Hospitalization"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Primary Health Care"}, {"QualifierName": ["classification", "diagnosis", "etiology", "therapy"], "DescriptorName": "Pulmonary Disease, Chronic Obstructive"}]}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Wedzicha J.A., Seemungal T.A. COPD exacerbations: defining their cause and prevention. Lancet. 2007;370:786\u2013796.", "ArticleIdList": ["PMC7134993", "17765528"]}, {"Citation": "Soci\u00e9t\u00e9 de pneumologie de langue fran\u00e7aise Prise en charge de la BPCO: recommandations pour la pratique clinique. Rev Mal Respir. 2010;27 S1\u201376, I\u2013XXXI.", "ArticleIdList": ["0"]}, {"Citation": "Hurst J.R., Vestbo J., Anzueto A., Locantore N., Mullerova H., Tal-Singer R. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363:1128\u20131138.", "ArticleIdList": ["20843247"]}, {"Citation": "Mathers C.D., Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS medicine. 2006;3:e442.", "ArticleIdList": ["PMC1664601", "17132052"]}, {"Citation": "Wedzicha J.A., Brill S.E., Allinson J.P., Donaldson G.C. Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Med. 2013;11:181.", "ArticleIdList": ["PMC3750926", "23945277"]}, {"Citation": "Piquet J., Chavaillon J.M., David P., Martin F., Blanchon F., Roche N. High-risk patients following hospitalisation for an acute exacerbation of COPD. Eur Respir J. 2013;42:946\u2013955.", "ArticleIdList": ["23349446"]}, {"Citation": "NICE. National Clinical Guideline Centre . 2010. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care.http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0033903/ [Acc\u00e8s au site le 15/09/2014]"}, {"Citation": "Wedzicha J.A. Exacerbations: etiology and pathophysiologic mechanisms. Chest. 2002;121:136S\u2013141S.", "ArticleIdList": ["PMC7094340", "12010842"]}, {"Citation": "Sethi S., Evans N., Grant B.J., Murphy T.F. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med. 2002;347:465\u2013471.", "ArticleIdList": ["12181400"]}, {"Citation": "Soci\u00e9t\u00e9 de pneumologie de langue fran\u00e7aise Recommandations pour la prise en charge de la BPCO\u00a0: antibioth\u00e9rapie des exacerbations/d\u00e9compensations. Rev Mal Respir. 2003;20:S65\u2013S68.", "ArticleIdList": ["0"]}, {"Citation": "Murphy T.F., Brauer A.L., Eschberger K., Lobbins P., Grove L., Cai X. Pseudomonas aeruginosa in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2008;177:853\u2013860.", "ArticleIdList": ["18202344"]}, {"Citation": "Tillie-Leblond I., Marquette C.H., Perez T., Scherpereel A., Zanetti C., Tonnel A.B. Pulmonary embolism in patients with unexplained exacerbation of chronic obstructive pulmonary disease: prevalence and risk factors. Ann Intern Med. 2006;144:390\u2013396.", "ArticleIdList": ["16549851"]}, {"Citation": "Cavailles A., Brinchault-Rabin G., Dixmier A., Goupil F., Gut-Gobert C., Marchand-Adam S. Comorbidities of COPD. Eur Respir Rev. 2013;22:454\u2013475.", "ArticleIdList": ["PMC9639181", "24293462"]}, {"Citation": "Agusti A., Edwards L.D., Rennard S.I., MacNee W., Tal-Singer R., Miller B.E. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One. 2012;7:e37483.", "ArticleIdList": ["PMC3356313", "22624038"]}, {"Citation": "Soci\u00e9t\u00e9 de pneumologie de langue fran\u00e7aise Recommandations pour la prise en charge de la BPCO\u00a0: exacerbations: diagnostic, s\u00e9v\u00e9rit\u00e9 et prise en charge. Rev Mal Respir. 2003;20:S56\u2013S64.", "ArticleIdList": ["12910085"]}, {"Citation": "Wilkinson T.M., Donaldson G.C., Hurst J.R., Seemungal T.A., Wedzicha J.A. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004;169:1298\u20131303.", "ArticleIdList": ["14990395"]}, {"Citation": "Boe J., Dennis J.H., O\u2019Driscoll B.R., Bauer T.T., Carone M., Dautzenberg B. European Respiratory Society Guidelines on the use of nebulizers. Eur Respir J. 2001;18:228\u2013242.", "ArticleIdList": ["11510796"]}, {"Citation": "Anthonisen N.R., Manfreda J., Warren C.P., Hershfield E.S., Harding G.K., Nelson N.A. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106:196\u2013204.", "ArticleIdList": ["3492164"]}, {"Citation": "Miravitlles M., Kruesmann F., Haverstock D., Perroncel R., Choudhri S.H., Arvis P. Sputum colour and bacteria in chronic bronchitis exacerbations: a pooled analysis. Eur Respir J. 2012;39:1354\u20131360.", "ArticleIdList": ["22034649"]}, {"Citation": "Thompson W.H., Nielson C.P., Carvalho P., Charan N.B., Crowley J.J. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med. 1996;154:407\u2013412.", "ArticleIdList": ["8756814"]}, {"Citation": "Aaron S.D., Vandemheen K.L., Hebert P., Dales R., Stiell I.G., Ahuja J. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med. 2003;348:2618\u20132625.", "ArticleIdList": ["12826636"]}, {"Citation": "National Heart Lung and Blood Institute, NIH and World Health Organization . 2014. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Executive summary. Updated February 2014.  http://www.goldcopd.org/uploads/users/files/GOLD_Report2014_Feb07.pdf [Acc\u00e8s au site le 15/09/2014]", "ArticleIdList": ["11463370"]}, {"Citation": "Agusti A.G., Carrera M., Barbe F., Munoz A., Togores B. Oxygen therapy during exacerbations of chronic obstructive pulmonary disease. Eur Respir J. 1999;14:934\u2013939.", "ArticleIdList": ["10573245"]}, {"Citation": "Moloney E.D., Kiely J.L., McNicholas W.T. Controlled oxygen therapy and carbon dioxide retention during exacerbations of chronic obstructive pulmonary disease. Lancet. 2001;357:526\u2013528.", "ArticleIdList": ["11229674"]}, {"Citation": "McCrory D.C., Brown C.D. Anti-cholinergic bronchodilators versus beta2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2002;4:CD003900.", "ArticleIdList": ["PMC8753782", "12519615"]}, {"Citation": "Niewoehner D.E., Erbland M.L., Deupree R.H., Collins D., Gross N.J., Light R.W. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med. 1999;340:1941\u20131947.", "ArticleIdList": ["10379017"]}, {"Citation": "Davies L., Angus R.M., Calverley P.M. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet. 1999;354:456\u2013460.", "ArticleIdList": ["10465169"]}, {"Citation": "Leuppi J.D., Schuetz P., Bingisser R., Bodmer M., Briel M., Drescher T. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA. 2013;309:2223\u20132231.", "ArticleIdList": ["23695200"]}, {"Citation": "Sullivan A., Edlund C., Nord C.E. Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis. 2001;1:101\u2013114.", "ArticleIdList": ["11871461"]}, {"Citation": "Fantin B., Duval X., Massias L., Alavoine L., Chau F., Retout S. Ciprofloxacin dosage and emergence of resistance in human commensal bacteria. J Infect Dis. 2009;200:390\u2013398.", "ArticleIdList": ["PMC2933399", "19563257"]}, {"Citation": "Chen D.K., McGeer A., de Azavedo J.C., Low D.E. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med. 1999;341:233\u2013239.", "ArticleIdList": ["10413735"]}, {"Citation": "Garcia-Vidal C., Almagro P., Romani V., Rodriguez-Carballeira M., Cuchi E., Canales L. Pseudomonas aeruginosa in patients hospitalised for COPD exacerbation: a prospective study. Eur Respir J. 2009;34:1072\u20131078.", "ArticleIdList": ["19386694"]}, {"Citation": "Lin S.H., Kuo P.H., Hsueh P.R., Yang P.C., Kuo S.H. Sputum bacteriology in hospitalized patients with acute exacerbation of chronic obstructive pulmonary disease in Taiwan with an emphasis on Klebsiella pneumoniae and Pseudomonas aeruginosa. Respirology. 2007;12:81\u201387.", "ArticleIdList": ["17207030"]}, {"Citation": "Christ-Crain M., Jaccard-Stolz D., Bingisser R., Gencay M.M., Huber P.R., Tamm M. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004;363:600\u2013607.", "ArticleIdList": ["14987884"]}, {"Citation": "Stolz D., Christ-Crain M., Bingisser R., Leuppi J., Miedinger D., Muller C. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest. 2007;131:9\u201319.", "ArticleIdList": ["17218551"]}, {"Citation": "Burtin C., Decramer M., Gosselink R., Janssens W., Troosters T. Rehabilitation and acute exacerbations. Eur Respir J. 2011;38:702\u2013712.", "ArticleIdList": ["21719481"]}, {"Citation": "Keenan S.P., Sinuff T., Cook D.J., Hill N.S. Which patients with acute exacerbation of chronic obstructive pulmonary disease benefit from noninvasive positive-pressure ventilation?. A systematic review of the literature. Ann Intern Med. 2003;138:861\u2013870.", "ArticleIdList": ["12779296"]}, {"Citation": "Brochard L. Mechanical ventilation: invasive versus noninvasive. Eur Resp J. 2003;47:31s\u2013s37.", "ArticleIdList": ["14621115"]}, {"Citation": "Soci\u00e9t\u00e9 fran\u00e7aise d\u2019anesth\u00e9sie-r\u00e9animation (SFAR), Soci\u00e9t\u00e9 de pneumologie de langue fran\u00e7aise (SPLF) et la Soci\u00e9t\u00e9 de r\u00e9animation de langue fran\u00e7aise (SRLF)  2006. Conf\u00e9rence de consensus\u00a0: ventilation non invasive au cours de l\u2019insuffisance respiratoire aigu\u00eb (nouveau-n\u00e9 exclu)http://www.splf.org/s/spip.php?.article486 [Acc\u00e8s au site le 15/09/2014]"}, {"Citation": "Ram F.S., Wedzicha J.A., Wright J., Greenstone M. Hospital at home for patients with acute exacerbations of chronic obstructive pulmonary disease: systematic review of evidence. BMJ. 2004;329:315.", "ArticleIdList": ["PMC506849", "15242868"]}, {"Citation": "Jeppesen E., Brurberg K.G., Vist G.E., Wedzicha J.A., Wright J.J., Greenstone M. Hospital at home for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;5:CD003573.", "ArticleIdList": ["22592692"]}, {"Citation": "Alrajab S., Smith T.R., Owens M., Areno J.P., Caldito G. A home telemonitoring program reduced exacerbation and healthcare utilization rates in COPD patients with frequent exacerbations. Telemed J. 2012;18:772\u2013776.", "ArticleIdList": ["23082792"]}, {"Citation": "Pedone C., Chiurco D., Scarlata S., Incalzi R.A. Efficacy of multiparametric telemonitoring on respiratory outcomes in elderly people with COPD: a randomized controlled trial. BMC Health Serv Res. 2013;13:82.", "ArticleIdList": ["PMC3680224", "23497109"]}, {"Citation": "Segrelles Calvo G., Gomez-Suarez C., Soriano J.B., Zamora E., Gonzalez-Gamarra A., Gonzalez-Bejar M. A home telehealth program for patients with severe COPD: the PROMETE study. Respir Med. 2014;108:453\u2013462.", "ArticleIdList": ["24433744"]}, {"Citation": "Pinnock H., Hanley J., McCloughan L., Todd A., Krishan A., Lewis S. Effectiveness of telemonitoring integrated into existing clinical services on hospital admission for exacerbation of chronic obstructive pulmonary disease: researcher blind, multicentre, randomised controlled trial. BMJ. 2013;347:6070.", "ArticleIdList": ["PMC3805483", "24136634"]}, {"Citation": "Roche N. [Position of the French Language Society of Pulmonology regarding the 2011 version of the GOLD document] Rev Mal Respir. 2012;29:637\u2013639.", "ArticleIdList": ["22682585"]}], "ReferenceList": []}], "History": [{"Year": "2014", "Month": "2", "Day": "27"}, {"Year": "2014", "Month": "3", "Day": "17"}, {"Year": "2014", "Month": "3", "Day": "31"}, {"Year": "2014", "Month": "12", "Day": "3", "Hour": "6", "Minute": "0"}, {"Year": "2014", "Month": "12", "Day": "3", "Hour": "6", "Minute": "0"}, {"Year": "2015", "Month": "2", "Day": "12", "Hour": "6", "Minute": "0"}, {"Year": "2014", "Month": "10", "Day": "22"}], "PublicationStatus": "ppublish", "ArticleIdList": ["25451635", "PMC7118899", "10.1016/j.lpm.2014.03.034", "S0755-4982(14)00463-1"]}}], "PubmedBookArticle": []}